SLC5A2 and hydrops fetalis: The SGLT2 inhibitor dapagliflozin has potential therapeutic benefits for HFpEF due to its anti‐inflammatory effects.[53] With the help of scRNA‐seq, researchers found that dapagliflozin's cardioprotective effects in HF are independent of SGLT2 inhibition and are primarily mediated through the suppression of macrophage‐driven inflammation and subsequent fibroblast activation.[121] A snRNA‐seq of failing and non‐failing human hearts helped identify unique cellular compositions and transcriptional profiles.